Meniere’s disease (MD)
Conditions
Interventions
Experimental group (patients with Meniere’s disease) :N/A
Control group (healthy subjects):N/A
Sponsors
Shenzhen Second People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosis of Meniere’s disease (MD): Conforming to the diagnostic criteria of the International Barany Association (2015), including typical symptoms (paroxysmal vertigo, fluctuating hearing loss, tinnitus or aural fullness). 2. Age range: 18–70 years old, regardless of gender. 3. Sample type: Peripheral blood or inner ear tissue samples obtained by surgery (e.g., temporal bone pathological specimens).
Exclusion criteria
Exclusion criteria: 1. Patients with unclear diagnosis:Patients with atypical clinical symptoms who cannot be clearly diagnosed with Meniere’s disease, such as those presenting with isolated vertigo without other typical manifestations including hearing loss or aural fullness, or those whose relevant auxiliary examination results are insufficient to support the diagnosis of Meniere’s disease.Patients complicated with other diseases that may cause vertigo and auditory symptoms, such as sudden sensorineural hearing loss, benign paroxysmal positional vertigo, vestibular neuritis, acoustic neuroma, etc. These diseases may interfere with the diagnosis of Meniere’s disease and the judgment of research results. 2. Issues with sample quality:Biological samples with severe hemolysis, clotting, contamination or other problems during collection, transportation or preservation, which may affect the accuracy of experimental test results.Samples with insufficient quantity to meet the requirements of experimental detection, making them unsuitable for qPCR and Western blot assays. 3. Special populations and other conditions:Pregnant or lactating women. Due to the particularity of their physiological state, they may have an impact on gene and protein expression. Moreover, some experimental tests conducted during pregnancy may pose potential risks.Patients who have recently (within one month) used drugs that may affect gene expression or protein levels, such as glucocorticoids and immunosuppressants. These drugs may interfere with experimental results and prevent them from truly reflecting the gene and protein expression status under disease conditions.Patients with severe systemic diseases such as heart, liver or kidney diseases, or those with mental illnesses, malignant tumors or other diseases that may affect research results or life expectancy. These diseases may exert a significant impact on the overall physiological state and immune system of the body, thereby interfering with the research on Meniere’s disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Protein expression profile; | — |
Countries
China
Contacts
Public ContactYanping Yu
Shenzhen Second People's Hospital
Outcome results
None listed